Clinical trial update: National Cancer Institute of Canada

Breast Cancer Research

Volumn 7, Issue 2, 2005, Pages 48-51

  Pritchard, Kathy ^a   Whelan, Tim ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b Juravinski Regional Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; OGX 011; PLACEBO; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANADA; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; INTERMETHOD COMPARISON; LYMPHEDEMA; MASTECTOMY; MEDICAL LITERATURE; METASTASIS; OSTEOPOROSIS; PNEUMONIA; POSTMENOPAUSE; QUALITY OF LIFE; RECURRENCE RISK; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MULTICENTER STUDIES; RADIOTHERAPY, ADJUVANT;

EID: 14844358496     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr979     Document Type: Article

References (12)

1. Trudeau ME, Eisenhauer EA, Higgins B, Letendre F, Lofters WS, Norris B, Vandenberg T, Delorme F, Muldal A: Docetaxel in patients with metastic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996, 14:422-428.
2. Trudeau ME, Crump M, Latreille J, Pritchard KI, Palmer M, Tu D, Shepherd L, Shear N, Shapiro L, Oldfield S, et al.: Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer: a phase I/II study of the National Cancer Institute of Canada Clinical Trials Group [abstract]. Pro Am Soc Clin Oncol 1999, 18:117a.
3. Trudeau ME, Crump M, Latreille J, Pritchard KI, Palmer M, Tu D, Shepherd L, Shear N, Shapiro L, Oldfield S, et al.: Escalating doses of docetaxel and epirubicin as first line therapy for metastatic breast cancer: A phase I/II study of the National Cancer Institute of Canada - Clinical Trials Group [abstract 443]. Proc Am Soc Clin Oncol 1999, 18:117a.
4. Parissenti AM, Gannon BR, Villeneuve DJ, Kirwan-rhude AF, Chadderton A, Gluck S: Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells. Int J Cancer 1999, 82:893-900.
5. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd L, Pater JL: Updated analysis of the NCIC CTG Ma.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in post-menopausal women with early stage breast cancer [abstract. Proc Am Soc Clin Oncol 2004, 22: 8s.
6. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd L, Pritchard KI, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Eng J Med 2003, 349:1793-1802.
7. The ATAC Trialists Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
8. The ATAC Trialists Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810.
9. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2004, 85:192.
10. Coombes RC, Hall E, Gibson L, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 2004, 350:1081-1091.
11. Ragaz J, Stewart DJ, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997, 337:956-962.
12. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997, 337:949-955.